Formosa Pharmaceuticals (台新藥) is a clinical stage biopharmaceutical company with primary focus in ophthalmology and oncology. 

Our flagship asset, APP13007 (Clobetasol Propionate ophthalmic suspension 0.05%) was recently approved by the US FDA (March, 2024) for the treatment of post-operative inflammation and pain following ocular surgery. 

In August, 2017, Formosa Pharmaceuticals completed the acquisition of Activus Pharma, based in Funabashi, Japan.  With the acquisition of the Activus Pure Nanoparticle Technology (APNT) Platform, Formosa Pharmaceuticals enters the ophthalmology disease area with two late-preclinical assets and the goal of expanding the platform’s scope and application.  APNT effectively reduces API particle size to improve dissolution and bioavailability without the drawbacks of heavy metal contamination other platforms often experience.

Formosa Pharmaceuticals, Inc.

Org chart

Teams

Offices